RBC Capital downgraded Verrica Pharmaceuticals (VRCA) to Sector Perform from Outperform with a price target of $2, down from $11.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRCA:
- Verrica Pharmaceuticals: Financial Struggles Amid Strategic Shifts
- Verrica Pharmaceuticals Undergoes Leadership and Financial Restructuring
- Verrica Pharmaceuticals reports Q3 EPS (43c), consensus (37c)
- Verrica to preset results on VP-315 at Fall Clinical Dermatology Conference
- Verrica Pharmaceuticals price target lowered to $10 from $15 at TD Cowen